Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $506,978.75 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 8,485 shares of the company's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $506,978.75. Following the completion of the transaction, the insider now owns 712 shares in the company, valued at $42,542. This represents a 92.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Irene Becklund also recently made the following trade(s):

• On Thursday, May 22nd, Irene Becklund sold 5,071 shares of Hims & Hers Health stock. The stock was sold at an average price of $53.51, for a total transaction of $271,349.21.
• On Tuesday, April 22nd, Irene Becklund sold 2,936 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.49, for a total value of $77,774.64.
• On Thursday, April 3rd, Irene Becklund sold 2,203 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.78, for a total value of $63,402.34.

Hims & Hers Health Stock Down 1.0%

Hims & Hers Health stock traded down $0.61 during midday trading on Tuesday, reaching $59.17. The stock had a trading volume of 35,141,346 shares, compared to its average volume of 21,323,036. The firm's 50-day moving average price is $45.77 and its 200 day moving average price is $38.46. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The firm has a market capitalization of $13.24 billion, a PE ratio of 139.02, a P/E/G ratio of 2.25 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same period last year, the company earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Truist Financial lowered their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Bank of America lifted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Needham & Company LLC increased their target price on Hims & Hers Health from $61.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $38.00.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC grew its holdings in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after acquiring an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Nuveen LLC purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $58,403,000. Finally, Yong Rong HK Asset Management Ltd acquired a new stake in Hims & Hers Health during the fourth quarter worth about $41,104,000. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.